Visibility Vol 11 Issue 3 & 4, 2017

The NEI-VFQ questionnaire was administered as part of the FAME phase 3 clinical trials. The driving subscale score (DSS), one of 12 subscale scores derived from the questionnaire, assesses driving difficulty in patients . The fluocinolone acetonide (FAc) 0.2μg/day implant is the only approved treatment for DME that continuously delivers therapy for 36 months with a single administration. This post hoc analysis was conducted to assess the relationship between improvement in visual acuity associated with 0.2μg/day FAc implant treatment and changes in the DSS over time and factors that may contribute to these findings.

Read More